Open Access Open Access  Restricted Access Subscription Access

An Indispensible Parameters of Propranolol Include Objectives, Mechanism of Action, Administration, Adverse Effects, Contra Indications, Toxicity and Health Care Outcomes

Srinivas G., Ramanjaneyulu D. V., Satyanarayana Murthy S., Muralinath E., Guruprasad M., Hari Kiran M., Shaik Mahabooob Basha, Kundara Giridhar Reddy, Kasireddy Gauthami, Mopoori Kalyan, Sai Charan B., Sainath Reddy T., Ramesh U., Rahul P., Rajitha V.

Abstract


Propanolol can be used to prevent acute ischemia attacks, treat migraines, treat restless legs syndrome, and reduce the sympathetic response in angina and tachyarrhythmias. When lowering a patient's heart rate and contractility is the intended outcome, propranolol can be administered in practically every situation. Propranolol is also used off-label in a number of other situations. For example, it is used to treat performance anxiety, a kind of social phobia, a mental illness characterized by flushing, sweating, and tachycardia due to the sympathetic nervous system being activated. The indications, dosage, contraindications, mechanism, and management of propranolol therapy by the multidisciplinary healthcare team are explained in this activity.


Full Text:

PDF

References


Nies, A. S., & Shand, D. G. (1975). Clinical pharmacology of propranolol. Circulation, 52(1),6-15. https://www.ahajournals.org/doi/abs/10.1161/01.cir.52.1.6

Dunn, F. G., & Frohlich, E. D. (1981). Pharmacokinetics, mechanisms of action, indications, and adverse effects of timolol maleate, a nonselective beta‐adrenoreceptor blocking agent. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1(3), 188-200. https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1002/j.1875-9114.1981.tb02540.x

Agent, B. A. R. B. Pr PROPRANOLOL HYDROCHLORIDE INJECTION USP. https://sandoz-ca.cms.sandoz.com/sites/default/files/Media%20Documents/pdf%20408.pdf

Drolet, B. A., Frommelt, P. C., Chamlin, S. L., Haggstrom, A., Bauman, N. M., Chiu, Y. E., ... & Frieden, I. J. (2013). Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics, 131(1), 128-140. https://publications.aap.org/pediatrics/article-abstract/131/1/128/30793/Initiation-and-Use-of-Propranolol-for-Infantile

Zaugg, M., Schaub, M. C., Pasch, T., & Spahn, D. R. (2002). Modulation of β‐adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action. British journal of anaesthesia, 88(1), 101-123. https://academic.oup.com/bja/article-abstract/88/1/101/258444

Gavali, D. K., Kulkarni, K. S., Kumar, A., & Chakraborty, B. S. (2009). Therapeutic class-specific signal detection of bradycardia associated with propranolol hydrochloride. Indian journal of pharmacology, 41(4), 162-166. https://journals.lww.com/iphr/fulltext/2009/41040/therapeutic_class_specific_signal_detection_of.4.aspx

Westfall, T. C., & Westfall, D. P. (2006). Adrenergic agonists and antagonists. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 11th ed. Edited by Brunton LL, Lazo JS, Parker KL. New York, McGraw-Hill, 237-315. http://ndl.ethernet.edu.et/bitstream/123456789/19620/1/1780.pdf#page=263

Waseem, R., Hussein, M. I. H., Salih, T. S. M., & Ahmed, S. M. G. (2023). Pharmacology of the autonomic nervous system. In Topics in Autonomic Nervous System. IntechOpen. https://www.intechopen.com/chapters/88194

Mladěnka, P., Applová, L., Patočka, J., Costa, V. M., Remiao, F., Pourová, J., ... & TOX‐OER and CARDIOTOX Hradec Králové Researchers and Collaborators. (2018). Comprehensive review of cardiovascular toxicity of drugs and related agents. Medicinalresearchreviews, 38(4),1332-1403. https://onlinelibrary.wiley.com/doi/full/10.1002/med.21476

MacCarthy, E. P., & Bloomfield, S. S. (1983). Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 3(4), 193-217. https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1002/j.1875-9114.1983.tb03252.x

Koraćević, G., Stojanović, M., Kostić, T., Lović, D., Zdravković, M., Koraćević, M., ... & Mićić, S. (2021). Contraindications differ widely among beta blockers and ought to be cited for an individual drug, not for the entire class. Current PharmaceuticalDesign, 27(40),4125-4132. https://www.benthamdirect.com/content/journals/cpd/10.2174/1381612827666210716162130

Lauterbach, M. (2019). Clinical toxicology of beta‐blocker overdose in adults. Basic & clinical pharmacology & toxicology, 125(2), 178-186. https://onlinelibrary.wiley.com/doi/abs/10.1111/bcpt.13231


Refbacks

  • There are currently no refbacks.